Keros Therapeutics, Inc. (KROS) Operating cash flow 2019–2025
Keros Therapeutics, Inc. (KROS) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
$107.5MFY2025 · since FY2019: -$16.0M → $107.5M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $107.5M | +166.8% |
| FY2024 | -$160.9M | -29.2% |
| FY2023 | -$124.5M | -77.7% |
| FY2022 | -$70.1M | -12.7% |
| FY2021 | -$62.1M | -68.5% |
| FY2020 | -$36.9M | -130.6% |
| FY2019 | -$16.0M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More KROS financial trends
KROS RevenueKROS Net incomeKROS Net marginKROS Gross profitKROS Gross marginKROS Operating incomeKROS Operating marginKROS Free cash flowKROS Capital expendituresKROS Return on equityKROS Stock buybacksKROS Dividends paidKROS Total assetsKROS Total liabilitiesKROS Shareholders’ equityKROS overview →